Faruqi & Faruqi, LLP Launches Investigation for Skye Bioscience Investors

Investigation of Claims Against Skye Biosciences

Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently conducting an investigation surrounding potential claims on behalf of investors in Skye Biosciences, Inc. This inquiry is particularly focused on allegations that Skye may have violated federal securities laws, particularly concerning the efficacy of their drug, nimacimab.

Investors who purchased or acquired securities in Skye between November 4, 2024, and October 3, 2025, are encouraged to examine their legal options as the deadline for seeking the role of lead plaintiff in this federal class action lawsuit is set for January 16, 2026. Faruqi & Faruqi's partner, James (Josh) Wilson, is urging those who suffered losses during this period to contact him directly for legal advice and assistance.

Allegations Against Skye Biosciences

The complaint alleges that Skye and its executives disseminated misleading statements regarding the drug nimacimab, claiming it was more effective than it turned out to be. Critical points outlined in the complaint include:
1. Ineffectiveness of Nimacimab: The defendant’s claims regarding nimacimab's efficacy and its clinical prospects were overstated.
2. Misleading Statements: The information shared with the public, including potential benefits and outcomes linked to the drug, was found to be materially false and misleading.
3. Stock Price Decline: Following the release of unfavorable trial results on October 6, 2025, Skye’s stock saw a dramatic decrease of $2.85 per share, a loss of about 60%, closing at $1.90.

These events have raised serious concerns among stakeholders, highlighting the importance of transparency and accountability in corporate practices.

Call to Action for Injured Investors

Faruqi & Faruqi invites shareholders and anyone with relevant information regarding Skye's conduct to participate in this investigation. They are especially interested in hearing from whistleblowers, current and former employees, and other shareholders. If you believe that you may have a claim against Skye, this is an opportunity to seek guidance from a reputable legal firm that has a history of recovering substantial amounts for investors since its inception in 1995.

If you are interested in learning more about this investigation or want to discuss the class action details, visit Faruqi & Faruqi’s official website or contact partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).

This investigation represents a crucial step for many investors who feel aggrieved and are seeking justice. Although becoming a lead plaintiff can carry certain responsibilities, it ensures that your interests are represented during court proceedings.

Conclusion

Faruqi & Faruqi maintains a solid reputation in the arena of securities law, with notable accomplishments that include the recovery of hundreds of millions for investors. The firm urges affected Skye Bioscience investors to reach out without delay to explore their rights and possible avenues for compensation.